Diabetic macular edema (DME) is the leading cause of vision loss in working-age adults with diabetes. Intravitreal anti-VEGF therapy is the established standard of care, and 10-year real-world data now characterize long-term effectiveness, injection burden trajectories, and the gap between trial and clinical practice outcomes.

A retrospective 10-year study of 774 eyes with DME demonstrates sustained functional and anatomical improvement: BCVA improved from 0.43 to 0.27 logMAR at year 1 and remained stable at 0.32 by year 10, with central macular thickness reducing from 423 μm to 279 μm. Injection frequency declined from 3.6 per year in year 1 to 0.29 by year 10. Real-world outcomes remained less favorable than pivotal trial results, largely attributed to undertreatment and patient heterogeneity, reinforcing the importance of structured monitoring and individualized treat-and-extend protocols to maintain anatomical gains.

Retinal specialists, ophthalmologists, and vitreoretinal surgeons managing DME will benefit from peer discussion of 10-year anti-VEGF real-world outcomes, undertreatment drivers, bispecific agent evidence, and optimal treat-and-extend protocol design.

How do real-world 10-year DME data showing gaps versus pivotal trial outcomes influence your monitoring protocols, injection frequency decisions, and patient counseling? What clinical or anatomical parameters guide your decision to switch or escalate anti-VEGF therapy in DME, and how do you structure a treat-and-extend regimen in patients with suboptimal response?